Minutes of the CVMP meeting 10-12 February 2026

Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Revision: 1, Status: Authorised

20th anniversary of European Medicines Agency's Patients' and Consumers' Working Party (PCWP), Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 June 2026, 13:30 (CEST) to 30 June 2026, 17:30 (CEST)

Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Epidyolex, cannabidiol, Date of authorisation: 19/09/2019, Revision: 21, Status: Authorised

Orientation guide for patient representatives and healthcare professionals - EMA building

Orientation guide for delegates - EMA building

Human medicines European public assessment report (EPAR): Advate, octocog alfa, Date of authorisation: 02/03/2004, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Caelyx pegylated liposomal, doxorubicin, Date of authorisation: 20/06/1996, Revision: 40, Status: Authorised